p53 and bcl-2 proteins as prognostic markers in human papillomavirus- associated cervical lesions

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2120-2130

  Kurvinen, K ^a   Syrjanen K ^a   Syrjanen S ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; UTERINE CERVICITIS; UTERINE CERVIX BIOPSY; VIRUS INFECTION; WART VIRUS;

EID: 0029937224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2120     Document Type: Article

References (38)

1. zur Hausen H: Papillomaviruses in human cancers. Mol Carcinogen 1:147-150, 1988
2. Riou G, Favre M, Jeannel D, et al: Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335:1171-1174, 1990
3. Münger K, Phelps WC, Bubb V, et al: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421, 1989
4. Hudson JB, Bedell MA, McCance DJ, et al: Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519-526, 1990
5. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990
6. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992
7. Kastan MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992
8. 1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994
9. Smith ML, Chen I-T, Zhan Q, et al: Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10:1053-1059, 1995
10. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
11. Chang F, Syrjänen S, Kurvinen K, et al: The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 88:174-186, 1993
12. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
13. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992
14. Leach FS, Tokino T, Meltzer P, et al: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993
15. Feitelson MA, Zhu M, Duan L-X, et al: Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117, 1993
16. Szekely L, Selivanova G, Magnusson KP, et al: EBNA-5, an Ebstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90:5455-5459, 1993
17. Zhang Q, Gutsch D, Kenney S: Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency. Mol Cell Biol 14:1929-1938, 1994
18. Hockenbery D, Nuñez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
19. Green DR, Bissonnette RP, Cotter TG: Apoptosis and cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1994, pp 37-52
20. Ryan JJ, Prochownik E, Gottlieb CA, et al: c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91:5878-5882, 1994
21. Gaulard P, d'Agay M-F, Peuchmaur M, et al: Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140:1089-1095, 1992
22. Hanada M, Delia D, Aiello A, et al: Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820-1828, 1993
23. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993
24. Ben-Ezra JM, Kornstein MJ, Grimes MM, et al: Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 145:1036-1040, 1994
25. Kataja V, Syrjänen S, Mäntyjärvi R, et al: Prognostic factors in cervical human papillomavirus infections. Sex Transm Dis 19:154-160, 1992
26. 2laser vaporization in the treatment of cervical and vaginal human papillomavirus (HPV) infections. Acta Obstet Gynecol Scand 68:619-625, 1989
27. National Cancer Institute Workshop: The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Acta Cytol 33:567-574, 1988
28. Kurvinen K, Hietanen S, Syrjänen K, et al: Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem. J Virol Methods 51:43-54, 1995
29. Laimins LA: The biology of human papillomaviruses: From warts to cancer. Infect Agents Dis 2:74-86, 1993
30. Crook T, Fisher C, Masterson PJ, et al: Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9:1225-1230, 1994
31. Crook T, Tidy JA, Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556, 1991
32. Shin DM, Kim J, Ro JY, et al: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994
33. Walts AE, Koeffler HP, Said JW: Localization of p53 protein and human papillomavirus in anogenitai squamous lesions: Immunohistochemical and in situ hybridization studies in benign, dysplastic. and malignant epithelia. Hum Pathol 24:1238-1242, 1993
34. Wiethege T, Voss B, Müller K-M: Detection of MDM2 - proto-oncogene in paraffin embedded human bronchial epithelium. J Cancer Res Clin Oncol 120:252-255, 1994
35. Koss LG: Carcinogenesis in the uterine cervix and human papillomavirus infection, in Syrjänen K, Gissmann L, Koss LG (eds): Papillomaviruses and Human Disease. Heidelberg, Germany, Springer-Verlag, 1987, pp 235-267
36. Hockenbery DM, Zutter M, Hickey W, et al: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965, 1991
37. Sinicrope FA, Ruan SB, Cleary KR, et al: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237-241, 1995
38. McKalip A, Pillai MR, Halabi S, et al: Apoptosis and cervical cancer. Abstract Book of the Fourteenth International Papillomavirus Conference, Quebec City, Canada, July 23-28, 1995, p 77